Tesamorelin
A stabilized GHRH analog that preferentially reduces visceral adipose tissue through targeted GH release.
Medically reviewed by Dr. Jonathan Snipes, MD. Last reviewed May 6, 2026.What It Is
Tesamorelin is a GHRH analog that has been extensively studied, particularly for its ability to reduce visceral (belly) fat. It's one of the few peptides with significant clinical data.
How It Works
It stimulates the pituitary to release GH, which then targets visceral fat stores. Clinical studies showed significant reduction in trunk fat without affecting subcutaneous fat the same way.
Who It's For
Adults concerned about visceral fat accumulation, metabolic health, and body composition. Particularly effective for those with excess abdominal fat.
Who Should Avoid It
Not for active cancer, pituitary tumors, or pregnancy. Monitor IGF-1 levels.
Protocol & Pricing
OBP Pharmacy Price
$100/15mg
You pay pharmacy price. No markup.
Starting Dose
20 units (0.6mg)
Form
Injectable vial (5mL, 3mg/mL, 15mg total)
Dosing Protocol
20 units subcutaneous injection daily for 5 days, 2 days off. Inject in evening to align with natural GH peak and improve sleep. 20 units = 0.2mL × 3mg/mL = 0.6mg per injection.
Beyond Use Date
90 Days from compounding (USP <797>)
Use within this window from the date your vial is compounded. BUD is set per USP <797> sterile compounding standards and printed on every label.
Stacking Guide
Stacks Well With
Related Peptides
Independently tested
Tesamorelin lab test reports
Every Tesamorelin batch dispensed by Optimal Balance Pharmacy is independently tested by Eagle Analytical Services (FDA-registered, A2LA ISO 17025 accredited) for sterility (ScanRDI) and bacterial endotoxin (USP <85>). The most recent report:
| Submission | Lot | Sample | Sterility | Endotoxin | |
|---|---|---|---|---|---|
| ETX-260319-0140 | 031826-05 | Tesamorelin 3mg/ml (5ML) TES3 | Pass | Pass <2 EU/mL / 375 EU/mL | Download |
Eagle Analytical Services is an independent FDA-registered laboratory, A2LA accredited to ISO 17025, based in Houston, Texas. They have no commercial relationship with PeptideRx. PeptideRx prescribes; Optimal Balance Pharmacy compounds and dispenses; Eagle tests every batch. Three separate companies. Browse our full quality program on the quality page.
Common questions about Tesamorelin
- What is tesamorelin?
- Tesamorelin is a 44-amino acid GHRH analog with a longer half-life than sermorelin. It binds GHRH receptors at the pituitary and stimulates endogenous growth hormone release. The molecule is FDA-approved as Egrifta for the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is also used off-label in age-management practices for body composition and visceral fat reduction.
- Is tesamorelin FDA-approved?
- Yes. Tesamorelin (brand name Egrifta) is FDA-approved for HIV-associated lipodystrophy. Off-label use for visceral adiposity in non-HIV patients is permissible under physician judgment. PeptideRx providers prescribe tesamorelin within their state's scope of practice.
- How is tesamorelin dosed at PeptideRx?
- The Egrifta-approved dose is 2 mg subcutaneously once daily. Many compounding clinics use a slightly lower 1 to 2 mg per day starting dose for non-HIV patients. Optimal Balance Pharmacy compounds tesamorelin against PeptideRx prescriptions; the per-dose draw depends on your vial concentration printed on your label.
- Where do I inject tesamorelin?
- Subcutaneous injection into the abdomen using a 31-gauge, 5/16-inch (8 mm) needle on a U-100 insulin syringe. Rotate sites within the abdomen with each injection. Most patients dose in the evening before bed; tesamorelin's longer half-life supports once-daily dosing.
- How is tesamorelin supplied?
- Compounded by Optimal Balance Pharmacy under a 503A patient-specific prescription. Ships pre-reconstituted and ready to inject in cold-chain packaging. Every batch is tested by Eagle Analytical Services for sterility and bacterial endotoxin; the Certificate of Analysis is published on this product page. Refrigerate per the printed label.